Hypertension

High blood pressure increases a patient's risk of heart attack, stroke and other diseases. Most people with hypertension have no symptoms. The Centers for Disease Control and Prevention (CDC) says nearly half of U.S. adults have hypertension, or high blood pressure, and only about 1 in 4 of those individuals has their hypertension under control. The World Health Organization (WHO) expects the epidemic of hypertension world-wide will exceed 1.56 billion people by 2025. Major efforts are underway to better control this primary risk factor through screenings, medication and invasive procedures such as renal denervation in severely uncontrolled patients.

Blood pressure

High blood pressure more than doubles risk of COVID-19 hospitalization

Adults that received three doses of an mRNA COVID vaccine were 2.6 times as likely to be hospitalized if they also had high blood pressure. 

July 22, 2022
Brain

RAAS inhibitors lower risk of aneurysm rupture among patients with high blood pressure

Researchers also noted that uncontrolled hypertension, exposure to second-hand smoke and untreated type 2 diabetes were all associated with a greater rupture risk.

June 3, 2022
cocaine heart failure HFrEF LVEF hospitalizations beta-blockers hypertension cardiology

How cocaine use affects outcomes for hospitalized heart failure patients

When cocaine users are hospitalized for heart failure, what should physicians expect? Are beta-blockers an effective treatment strategy? 

June 3, 2022
Renal denervation is associated with improved blood pressure (BP) control and a reduced risk of adverse cardiovascular outcomes, according to two late-breaking clinical trials presented at EuroPCR 2022 in Paris. Both clinical trials focused on three-year data related to Medtronic’s Symplicity Spyral Renal Denervation (RDN) System, which was designed to lower BP through the use of a curling catheter that ablates overactive nerves.

Renal denervation improves blood pressure control, lowers risk of adverse cardiovascular outcomes

Two late-breaking clinical trials at EuroPCR 2022 in Paris focused on the potential benefits of renal denervation.

May 17, 2022

Arterial stiffness may predict type 2 diabetes risk better than high blood pressure

Researchers tracked data from more than 11,000 adult patients, sharing their findings in Hypertension.

May 16, 2022
The American College of Cardiology (ACC) annual meeting ACC.22 is the premier source for the latest cardiac science. #ACC22 Here are links to all the late breaking studies, trials and late-breaker science at the annual meeting conference. #ACC2022 #ACC

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C. 

April 13, 2022
The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Renal denervation linked to significant blood pressure reductions after 3 years

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet

April 6, 2022
These quinapril HCl/hydrochlorothiazide tablets, which Pfizer sells under the name Accuretic, are included in the voluntary FDA recall.

FDA announces recall of hypertension medications due to potential cancer risk

The voluntary recall includes quinapril HCl/hydrochlorothiazide tablets sold by Pfizer and authorized generics of that same medication. 

March 23, 2022